Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting

Aim: To compare all-cause and acute lymphoblastic leukemia (ALL)-related healthcare resource utilization (HCRU) and costs among patients receiving inotuzumab ozogamicin (InO) and blinatumomab (Blina) for ALL in the first relapsed/refractory (R/R) setting. Patients & methods: We studied retrospecti...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Alexander Russell-Smith, Louise Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah Webb, Stephanie Dorman, Richa Shah
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Becaris Publishing Limited 2023-12-01
Ráidu:	Journal of Comparative Effectiveness Research
Fáttát:	acute lymphoblastic leukemia costs health care resource utilization medications relapse/refractory
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!